SELECT COUNTRY
VIEW ALL
AFRICA
AMERICAS
ASIA
EUROPE
OCEANIA
ALGERIA
ANGOLA
ARGENTINA
AUSTRALIA
AZERBAIJAN
BAHREIN
BELGIUM
BENIN
BOLIVIA
BOTSWANA
BRAZIL
BRUNEI
BURKINA FASO
CAMEROON
CANADA
CENTRAL AFRICAN REPUBLIC
CHAD
CHILE
CHINA
COLOMBIA
COTE D’IVOIRE
CUBA
CZECH REPUBLIC
DOMINICAN REPUBLIC
DRC
ECUADOR
EGYPT
EQUATORIAL GUINEA
ETHIOPIA
FINLAND
FRANCE
GABON
GHANA
GREENLAND
GUATEMALA
GUINEA
GUYANA
HUNGARY
ICELAND
INDIA
INDONESIA
IRAN
IRAQ
ITALY
JAMAICA
JAPAN
KAZAKHSTAN
KENYA
KUWAIT
LESOTHO
LIBERIA
LIBYA
MADAGASCAR
MALAWI
MALAYSIA
MALI
MAURITANIE
MEXICO
MONGOLIA
MOROCCO
MOZAMBIQUE
NAMIBIA
NETHERLANDS
NICARAGUA
NIGER
NIGERIA
NORWAY
PANAMA
PAPUA NEW GUINEA
PARAGUAY
PERU
PHILIPPINES
POLAND
QATAR
REPUBLIC OF CONGO
RUSSIA
RWANDA
SAUDI ARABIA
SENEGAL
SIERRA LEONE
SINGAPORE
SLOVENIA
SOMALI
SOUTH AFRICA
SOUTH KOREA
SPAIN
SUDAN
SWEDEN
TAIWAN
TANZANIA
THAILAND
TOGO
TRINDAD & TOBAGO
TURKEY
TURKMENISTAN
UAE
UGANDA
UKRAINE
UNITED KINGDOM
UNITED STATES
VENEZUELA
VIETNAM
ZAMBIA
ZIMBABWE
CAMEROON: LATEST INTERVIEWS MORE INTERVIEWS
"By developing intra-African energy infrastructure, we can reduce costs, improve energy access, and encourage local refining and petrochemical industries."
"Since we acquired Accugas in late 2017, the volumes of gas transported, the number of significant customers served, and our contribution to thermal power generation in Nigeria have each more than doubled."
"To us, energy poverty poses a more immediate existential challenge than climate change."
"Africa remains our primary focus, providing many opportunities driven by a vibrant mining industry, as well as less competition and the possibility of attaining a larger market share."
CAMEROON: RECENTLY RELEASED PUBLICATIONS
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
